Comparative Pharmacology
Head-to-head clinical analysis: BENTYL PRESERVATIVE FREE versus JESDUVROQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL PRESERVATIVE FREE versus JESDUVROQ.
BENTYL PRESERVATIVE FREE vs JESDUVROQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist (anticholinergic) that inhibits the action of acetylcholine on structures innervated by postganglionic parasympathetic nerves. It reduces smooth muscle spasm in the gastrointestinal tract by blocking M1, M2, and M3 receptors, with a predominant effect on M3 receptors in the gut.
JESDUVROQ is a small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, blocking retinoblastoma protein phosphorylation and inducing G1 cell cycle arrest.
20 mg orally three times daily; may increase to 40 mg three times daily if tolerated.
IV: 10 mg/kg every 4 weeks, infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life: 1.9–3.3 hours (in healthy adults). Clinically, short half-life necessitates frequent dosing for sustained effect.
Terminal elimination half-life is 12-15 hours in patients with normal renal function (CrCl >90 mL/min). Half-life increases with renal impairment (up to >30 hours in end-stage renal disease), requiring dose adjustment.
Renal: ~50% (mostly as metabolites), Biliary/Fecal: ~40% (as unchanged drug and metabolites), minor via enterohepatic circulation.
Primarily renal elimination (70-80% unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for 15-20% as metabolites, with less than 5% unchanged in feces.
Category C
Category C
Anticholinergic
Anticholinergic